000			01851nam a2200325 4500
001			7583
010			_a9291681229
090			_a7583
100			_a20030115d2002 y0pory50 ba
101			_aeng
200			_aReport on the risk assessment of GHB in the framework of the joint action on new synthetic drugs _fEuropean Monitoring Centre for Drugs and Drug Addiction
210			_aLuxembourg _cOffice for Official Publications of the European Communities _d2002
215			_a92 p. _d21 cm
225			_aImplemention of the joint action _v4
300			_aInformação sobre European Monitoring Centre for Drugs and Drug Addiction pode ser encontrada no site: https://www.emcdda.org
330			_aReport on the risk assessment of GHB in the framework of the joint action on new synthetic drugs. Europol-EMCDDS progress report on GHB in accordance with Article 3 of the joint action of 16 June 1997 concerning the information exchange, risk assessment and the control of new synthetic drugs. Use of GHB as a medicinal product (EMEA). Review of the pharmacotoxicological data on gamma-hydroxybutyric acid (GHB). Sociological and criminological (Europol) evidence on the risk of GHB. Public health risk of GHB - epidemiological evidence.
606			_aDROGAS ILÍCITAS _96631
606			_aSUBSTÂNCIAS PSICOTRÓPICAS _96333
606			_aCOOPERAÇÃO INTERNACIONAL _9581
606			_aSAÚDE PÚBLICA _91370
606			_aEUROPOL _9103050
606			_aCONSELHO DA EUROPA _96334
710			_aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION - EMCDDA _95764
852			_jDRO321